Senti Biosciences, Inc. (SNTI)
(Delayed Data from NSDQ)
$2.58 USD
-0.17 (-6.02%)
Updated Aug 28, 2024 03:51 PM ET
After-Market: $2.55 -0.03 (-0.97%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Income Statements
Fiscal Year end for Senti Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 4 | 0 | NA | NA |
Cost Of Goods | 0 | 0 | 0 | NA | NA |
Gross Profit | 3 | 4 | 0 | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 95 | 75 | 4 | 0 | 0 |
Income After Depreciation & Amortization | -93 | -71 | -4 | 0 | 0 |
Non-Operating Income | 9 | 12 | 0 | NA | NA |
Interest Expense | 0 | 0 | 0 | NA | NA |
Pretax Income | -83 | -58 | -4 | NA | NA |
Income Taxes | 0 | 0 | 0 | NA | NA |
Minority Interest | 0 | 0 | 0 | NA | NA |
Investment Gains/Losses | 0 | 0 | 0 | NA | NA |
Other Income/Charges | 0 | 0 | 0 | NA | NA |
Income From Cont. Operations | -83 | -58 | -4 | NA | NA |
Extras & Discontinued Operations | 12 | 0 | 0 | NA | NA |
Net Income (GAAP) | -71 | -58 | -4 | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -87 | -67 | -4 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 5 | 4 | 0 | NA | NA |
Income After Depreciation & Amortization | -93 | -71 | -4 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.44 | 2.61 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -18.80 | -22.30 | NA | NA | NA |
Diluted Net EPS (GAAP) | -16.00 | -22.30 | -1.70 | NA | NA |
Fiscal Year end for Senti Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.34 | 0.94 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.34 | 0.94 |
SG&A, R&D, and Dept/Amort Expenses | 13.36 | 16.30 | 9.38 | 44.21 | 20.57 |
Income After SG&A, R&D, and Dept/Amort Expenses | -13.36 | -16.30 | -9.38 | -43.87 | -19.63 |
Non-Operating Income | 2.15 | 4.19 | 0.01 | 7.26 | 0.94 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -11.20 | -12.11 | -9.37 | -36.62 | -18.70 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -11.20 | -12.11 | -9.37 | -36.62 | -18.70 |
Extras & Discontinued Operations | 0.00 | 0.00 | -9.34 | 21.69 | 0.00 |
Net Income (GAAP) | -11.20 | -12.11 | -18.72 | -14.92 | -18.70 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 4.57 | 4.57 | 4.47 | 4.45 | 4.43 |
Diluted EPS Before Non-Recurring Items | -2.45 | -2.60 | -4.20 | -2.50 | -4.20 |
Diluted Net EPS (GAAP) | -2.45 | -2.60 | -4.20 | -3.40 | -4.20 |